Management of the metabolic syndrome - Nicotinic acid

Endocrinology and Metabolism Clinics of North America

Volumn 33, Issue 3, 2004, Pages 557-575

  Meyers, C Daniel ^a   Kashyap, Moti L ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOFIBRATE; COLESTIPOL; DEXTROTHYROXINE; ENDURACIN; ESTROGEN; INSULIN; LIPID; MEVINOLIN; NICOTINIC ACID; SIMVASTATIN; SLO NIACIN;

ACANTHOSIS NIGRICANS; ADIPOCYTE; ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; BURNING SENSATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSLIPIDEMIA; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; INSULIN RESISTANCE; LIPOLYSIS; LIVER TOXICITY; METABOLIC SYNDROME X; MYOPATHY; PATIENT; POPULATION RESEARCH; PRIORITY JOURNAL; RETINA MACULA EDEMA; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TREATMENT INDICATION;

ANTILIPEMIC AGENTS; HUMANS; METABOLIC SYNDROME X; NIACIN;

EID: 3242740828     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2004.03.014     Document Type: Review

References (70)

1. Wong N.D., Sciammarella M.G., Polk D., Gallagher A., Miranda-Peats L., Whitcomb B., et al. The metabolic syndrome, diabetes, and subclinical atherosclerosis assessed by coronary calcium. J Am Coll Cardiol. 41:2003;1547-1553
2. Wong N.D., Pio J.R., Franklin S.S., L'Italien G.J., Kamath T.V., Williams G.R. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol. 91:2003;1421-1426
3. Ruotolo G., Howard B.V. Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep. 4:2002;494-500
4. [No author listed]. Clofibrate and niacin in coronary heart disease. JAMA. 231:1975;360-381
5. Carlson L.A., Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 223:1988;405-418
6. Cohn G., Valdes G., Capuzzi D.M. Pathophysiology and treatment of the dyslipidemia of insulin resistance. Curr Cardiol Rep. 3:2001;416-423
7. Elam M.B., Hunninghake D.B., Davis K.B., Garg R., Johnson C., Egan D., et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA. 284:2000;1263-1270
8. Grundy S.M., Vega G.L., McGovern M.E., Tulloch B.R., Kendall D.M., Fitz-Patrick D., et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med. 162:2002;1568-1576
9. Spies T.D., Cooper C., Blankenhorn N.M. The use of nicotinic acid in the treatment of pellagra. JAMA. 110:1938;622
10. US Institute of Medicine. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. 2000;National Academy Press, Washington, DC
11. Altschul R., Hoffer A., Stephen J.D. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys. 54:1955;558-559
12. Knopp R.H., Ginsberg J., Albers J.J., Hoff C., Ogilvie J.T., Warnick G.R., et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 34:1985;642-650
13. Knopp R.H., Alagona P., Davidson M., Goldberg A.C., Kafonek S.D., Kashyap M., et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 47:1998;1097-1104
14. McKenney J.M., Proctor J.D., Harris S., Chinchili V.M. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. 271:1994;672-677
15. Superko H.R., Krauss R.M. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis. 95:1992;69-76
16. Johansson J., Carlson L.A. The effects of nicotinic acid treatment on high density lipoprotein particle size subclass levels in hyperlipidaemic subjects. Atherosclerosis. 83:1990;207-216
17. Sakai T., Kamanna V.S., Kashyap M.L. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol. 21:2001;1783-1789
18. Gurakar A., Hoeg J.M., Kostner G., Papadopoulos N.M., Brewer H.B. Jr. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis. 57:1985;293-301
19. Kashyap M.L., McGovern M.E., Berra K., Guyton J.R., Kwiterovich P.O., Harper W.L., et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 89:2002;672-678
20. Chesney C.M., Elam M.B., Herd J.A., Davis K.B., Garg R., Hunninghake D., et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am Heart J. 140:2000;631-636
21. Brown S.L., Sobel B.E., Fujii S. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. Circulation. 92:1995;767-772
22. Morrow J.D., Parsons W.G. III, Roberts L.J. II. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins. 38:1989;263-274
23. Morrow J.D., Awad J.A., Oates J.A., Roberts L.J. II. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol. 98:1992;812-815
24. Gray D.R., Morgan T., Chretien S.D., Kashyap M.L. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med. 121:1994;252-258
25. Jungnickel P.W., Maloley P.A., Vander Tuin E.L., Peddicord T.E., Campbell J.R. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med. 12:1997;591-596
26. Gaut Z.N., Pocelinko R., Solomon H.M., Thomas G.B. Oral glucose tolerance, plasma insulin, and uric acid excretion in man during chronic administration of nicotinic acid. Metabolism. 20:1971;1031-1035
27. Kahn S.E., Beard J.C., Schwartz M.W., Ward W.K., Ding H.L., Bergman R.N., et al. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes. 38:1989;562-568
28. Garg A., Grundy S.M. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA. 264:1990;723-726
29. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 86:2000;943-949
30. Pan J., Lin M., Kesala R.L., Van J., Charles M.A. Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. Diabetes Obes Metab. 4:2002;255-261
31. Kane M.P., Hamilton R.A., Addesse E., Busch R.S., Bakst G. Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes. Pharmacotherapy. 21:2001;1473-1478
32. Parsons W.B. Jr. Studies of nicotinic acid use in hypercholesterolemia. Arch Intern Med. 107:1961;653-667
33. Mullin G.E., Greenson J.K., Mitchell M.C. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med. 111:1989;253-255
34. Fischer D.J., Knight L.L., Vestal R.E. Fulminant hepatic failure following low-dose sustained-release niacin therapy in hospital. West J Med. 155:1991;410-412
35. Dalton T.A., Berry R.S. Hepatotoxicity associated with sustained-release niacin. Am J Med. 93:1992;102-104
36. Capuzzi D.M., Guyton J.R., Morgan J.M., Goldberg A.C., Kreisberg R.A., Brusco O.A., et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol. 82:1998;74U-81U. [discussion: 85U-6U]
37. Parsons W.B. Jr. Activation of peptic ulcer by nicotinic acid. Report of five cases. JAMA. 173:1960;1466-1470
38. Gibbons L.W., Gonzalez V., Gordon N., Grundy S. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med. 99:1995;378-385
39. Stals H., Vercammen C., Peeters C., Morren M.A. Acanthosis nigricans caused by nicotinic acid: case report and review of the literature. Dermatology. 189:1994;203-206
40. Gharavi A.G., Diamond J.A., Smith D.A., Phillips R.A. Niacin-induced myopathy. Am J Cardiol. 74:1994;841-842
41. Callanan D., Blodi B.A., Martin D.F. Macular edema associated with nicotinic acid (niacin). JAMA. 279:1998;1702
42. Svedmyr N., Harthon L., Lundholm L. The relationship between the plasma concentration of free nicotinic acid and some of its pharmacologic effects in man. Clin Pharmacol Ther. 10:1969;559-570
43. Meyers C.D., Carr M.C., Park S., Brunzell J.D. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med. 139:2003;996-1002
44. Chojnowska-Jezierska J., Adamska-Dyniewska H. Efficacy and safety of one-year treatment with slow-release nicotinic acid. Monitoring of drug concentration in serum. Int J Clin Pharmacol Ther. 36:1998;326-332
45. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 345:2001;1583-1592
46. Keenan J.M., Fontaine P.L., Wenz J.B., Myers S., Huang Z.Q., Ripsin C.M. Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med. 151:1991;1424-1432
47. Aronov D.M., Keenan J.M., Akhmedzhanov N.M., Perova N.V., Oganov R.Y., Kiseleva N.Y. Clinical trial of wax-matrix sustained-release niacin in a Russian population with hypercholesterolemia. Arch Fam Med. 5:1996;567-575
48. Grundy S.M., Mok H.Y., Zech L., Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res. 22:1981;24-36
49. Blum C.B., Levy R.I., Eisenberg S., Hall M. 3rd, Goebel R.H., Berman M. High density lipoprotein metabolism in man. J Clin Invest. 60:1977;795-807
50. Shepherd J., Packard C.J., Patsch J.R., Gotto A.M. Jr., Taunton O.D. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest. 63:1979;858-867
51. Kamanna V.S., Kashyap M.L. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep. 2:2000;36-46
52. Jin F.Y., Kamanna V.S., Kashyap M.L. Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol. 19:1999;1051-1059
53. Ganji S.H., Xing Y., Kamanna V.S., Kashyap M. Niacin selectively inhibits hepatocyte DGAT2 but not DGAT1, key enzymes for triglyceride synthesis. Arterioscler Thromb Vasc Biol. 23:2003;50a
54. Jin F.Y., Kamanna V.S., Kashyap M.L. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 17:1997;2020-2028
55. Carlson L.A., Oro L. The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis. Acta Med Scand. 172:1962;641-645
56. Aktories K., Jakobs K.H., Schultz G. Nicotinic acid inhibits adipocyte adenylate cyclase in a hormone-like manner. FEBS Lett. 115:1980;11-14
57. Holm C., Osterlund T., Laurell H., Contreras J.A. Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. Annu Rev Nutr. 20:2000;365-393
58. Lorenzen A., Stannek C., Lang H., Andrianov V., Kalvinish I., Schwabe U. Characterization of a G protein-coupled receptor for nicotinic acid. Mol Pharmacol. 59:2001;349-357
59. Lorenzen A., Stannek C., Burmeister A., Kalvinsh I., Schwabe U. G protein-coupled receptor for nicotinic acid in mouse macrophages. Biochem Pharmacol. 64:2002;645-648
60. Wise A., Foord S.M., Fraser N.J., Barnes A.A., Elshourbagy N., Eilert M., et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 278:2003;9869-9874
61. Soga T., Kamohara M., Takasaki J., Matsumoto S., Saito T., Ohishi T., et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun. 303:2003;364-369
62. Tunaru S., Kero J., Schaub A., Wufka C., Blaukat A., Pfeffer K., et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 9:2003;352-355
63. Wang W., Basinger A., Neese R.A., Shane B., Myong S.A., Christiansen M., et al. Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am J Physiol Endocrinol Metab. 280:2001;E540-E547
64. King J.M., Crouse J.R., Terry J.G., Morgan T.M., Spray B.J., Miller N.E. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am J Med. 97:1994;323-331
65. Cashin-Hemphill L., Mack W.J., Pogoda J.M., Sanmarco M.E., Azen S.P., Blankenhorn D.H. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 264:1990;3013-3017
66. Brown G., Albers J.J., Fisher L.D., Schaeffer S.M., Lin J.T., Kaplan C., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1990;1289-1298
67. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 8:1986;1245-1255
68. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497
69. Canner P.L., Furberg C.D., McGovern M.E. Niacin decreases myocardial infarction and total mortality in patients with impaired fasting glucose or glucose intolerance: results from the coronary drug project. Circulation. 106:(Suppl):2002;3138
70. Robins S.J., Collins D., Wittes J.T., Papademetrion V., Deedwania P.C., Schaefer E.J., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 285:2001;1585-1591